Y-mAbs Therapeutics (YMAB) Tops Q1 EPS by 8c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.9 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist